Weidinger G, Ohlmann M, Schlereth B, Sutter G, Niewiesk S
Institute of Virology and Immunobiology, University of Wuerzburg, Versbacher Str. 7, 97078 Wurzburg, Germany.
Vaccine. 2001 Apr 6;19(20-22):2764-8. doi: 10.1016/s0264-410x(00)00531-4.
Modified vaccinia virus Ankara (MVA) has been used as an experimental vaccine vector against respiratory infections. We have tested the safety and immunogenicity of a recombinant virus expressing the hemagglutinin of measles virus (MVA-MV-H) using the mouse model of measles virus induced encephalitis and the cotton rat model for respiratory infection. MVA-MV-H proved to induce a TH1 response, neutralizing antibodies and conferred protection against both encephalitis and lung infection. The cotton rat is very sensitive to infection with replication competent vaccinia virus. In these animals MVA-MV-H proved to be a very well tolerated vaccine. However, the efficiency in the presence of MV specific maternal antibodies was low (even using a prime-boost strategy) and therefore might have to be improved.
安卡拉痘苗病毒（MVA）已被用作针对呼吸道感染的实验性疫苗载体。我们使用麻疹病毒诱导的脑炎小鼠模型和呼吸道感染的棉鼠模型，测试了表达麻疹病毒血凝素的重组病毒（MVA-MV-H）的安全性和免疫原性。结果证明，MVA-MV-H可诱导TH1反应、产生中和抗体，并对脑炎和肺部感染均具有保护作用。棉鼠对具有复制能力的痘苗病毒感染非常敏感。在这些动物中，MVA-MV-H被证明是一种耐受性良好的疫苗。然而，在存在麻疹病毒特异性母源抗体的情况下，其效率较低（即使采用初免-加强策略），因此可能需要改进。
